Compare AbCellera Biologics Inc (ABCL) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Endeavour Silver Corp — how do they compare? AbCellera Biologics Inc trades at $8.93 (market cap $2.85B), while Endeavour Silver Corp trades at $10.88 (market cap $3.03B). The key difference: AbCellera Biologics Inc and Endeavour Silver Corp are close in size by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Endeavour Silver Corp nearer its low. Which is the better fit depends on your goals.
| ABCL | EXK | |
|---|---|---|
Market Cap | $2.85B | $3.03B |
Sector | Health | Basic Materials |
52-Week High | $9.76 | $14.12 |
52-Week Low | $2.78 | $5.31 |
Enterprise Value | $2.45B | $3.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
EXK is trading at $9.54, up 8.04% today, with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with Q2 2026 earnings matching estimates and revenue growth from $468M in 2025 to $737M projected for 2026. Recent news highlights a $25M credit facility and operational expansion at Terronera mine.
Outlook remains positive with analyst consensus price target of $15.50 (62% upside), though risks include volatile earnings history and elevated P/E ratio of 51.2. The stock offers growth potential through silver production expansion but faces commodity price sensitivity and execution risks in mine development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
